Weekly Research Analysts’ Ratings Updates for Nektar Therapeutics (NKTR)

Several analysts have recently updated their ratings and price targets for Nektar Therapeutics (NASDAQ: NKTR):

• 12/8/2025 – Nektar Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Nektar Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/26/2025 – Nektar Therapeutics is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $102.00 price target on the stock.
• 11/25/2025 – Nektar Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Nektar Therapeutics had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $121.00 price target on the stock, up previously from $99.00.
• 11/19/2025 – Nektar Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/16/2025 – Nektar Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/8/2025 – Nektar Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.

Insider Buying and Selling

In related news, insider Jonathan Zalevsky sold 1,157 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $54.28, for a total transaction of $62,801.96. Following the completion of the sale, the insider owned 18,971 shares of the company’s stock, valued at $1,029,745.88. This represents a 5.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Mark Andrew Wilson sold 630 shares of the company’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $54.28, for a total value of $34,196.40. Following the transaction, the insider directly owned 21,585 shares in the company, valued at approximately $1,171,633.80. The trade was a 2.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,994 shares of company stock worth $216,794 in the last 90 days. 3.71% of the stock is owned by corporate insiders.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.